-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
· In addition, an Asian population subgroup analysis of carmelina® cardiovascular outcome trials showed that in adults with type 2 diabetes in Asia with a higher risk of cardioneedle, Liglitatin had similar cardiovascular and kidney safety characteristics compared to placebo Bronger Ingham published the results of the Asian subgroup analysis of the CAROLINA® cardiovascular outcome trial, focusing on asian adults with type 2 diabetes with increased cardiovascular risk.
the results, published in Diabetology International, showed that Liglitatin did not increase cardiovascular risk in the Asian population compared to Gremerin, and was consistent with the results of the entire CAROLINA® study population.
, the prevalence of type 2 diabetes in Asia has increased rapidly.
32019, the International Diabetes Federation estimates that more than half (251 million) of the world's 463 million people with diabetes are in Southeast Asia and the Western Pacific.
4 pre-set CAROLINA® subgroup analysis included 933 Asian adult patients, accounting for 15.5 percent of the 6,033 subjects in the CAROLINA® study.
Asian subjects in the CAROLINA ® study, liglitatin had a lower risk of hypoglycemia and a lower risk of weight gain than gremetin therapy.
13.1 per cent of Asian patients treated with liglitatin had any severe hypoglycemia, while 42.1 per cent of Asian patients treated with glitatin.
weight loss in the ligliglitin treatment group, with an average difference of -1.82 kg compared to Gremethal.
CAROLINA ® and CARMELINA® are two cardiovascular outcome trials of Liglitin that provide the most comprehensive data set of long-term safety of DPP-4-inhibitors.
A subgroup analysis of the CARMELINA® trial, published in The International Journal of Diabetology in October 2019, showed that liglitatin did not increase the risk of cardiovascular or kidney events in adults with type 2 diabetes in Asia who were at high risk of heart and/or kidney disease compared to placebos.
these results are consistent with those of ® carmelina study population as a whole.
these trials demonstrate the cardiovascular and kidney safety characteristics of liglitatin in a wide range of adults with type 2 diabetes in Asia.
.